Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 574 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07514052Recruiting
Predicting Response to Selinexor Treatment in Relapsed Multiple Myeloma
This study tests whether doctors can predict which patients with relapsed or hard-to-treat multiple myeloma will respond well to a drug called selinexor. Researchers will collect blood and bone marrow samples to identify markers that help personalize treatment decisions.
Taiyuan, ShanxiAges 18 years+ - NCT07529782RecruitingPhase 1
Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07547007Recruiting
Exercise Program to Improve Life Quality After Myeloma Treatment
This study tests whether a 6-month personalized exercise program—done partly at home and partly at a center—can improve quality of life for patients with multiple myeloma (a blood cancer) who are receiving ongoing chemotherapy or targeted drugs. The program is tailored to your abilities and fits into your regular hospital visits.
AnnecyAges 61 years+ - NCT07558915RecruitingPhase 1
Testing RO7851624 for Relapsed Multiple Myeloma
This Phase 1 trial tests a new drug called RO7851624 in patients whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to understand how safe and effective this drug is.
Parkville, VictoriaAges 18 years+ - NCT07559799Recruiting
Melflufen and Dexamethasone for Relapsed Multiple Myeloma
This study tracks how melflufen (a cancer-fighting drug) combined with dexamethasone works in patients with multiple myeloma that has returned or stopped responding to previous treatments. Researchers will monitor your health and quality of life over time to understand the treatment's real-world effectiveness.
Freiburg im BreisgauAges 18 years+ - NCT07564219Recruiting
Beta-Hydroxybutyrate to Boost CAR-T Cell Therapy in Multiple Myeloma
This trial tests whether a natural metabolite called beta-hydroxybutyrate can strengthen CAR-T cell therapy (a type of cancer-fighting cell treatment) in multiple myeloma patients. The goal is to help your immune cells work better against your cancer.
Hamburg, Free and Hanseatic City of HamburgAges 18 years+ - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07581704RecruitingPhase 1
Sirolimus plus immunotherapy for relapsed multiple myeloma
This study tests whether a drug called sirolimus, given before certain immunotherapy treatments (teclistamab or talquetamab), helps these treatments work better against multiple myeloma. These immunotherapies teach your immune cells to attack myeloma cells.
Iowa City, IowaAges 18 years+ - NCT07582354Recruiting
Understanding Multiple Myeloma Differences Between Patients
This study collects information and samples from people with multiple myeloma or related blood disorders to understand why the disease affects people differently. Researchers will use this information to develop better, personalized treatment approaches.
Bologna, BoAges 18 years+ - NCT07582432RecruitingPhase 3
Gamunex for Blood Cancer Patients With Low Antibodies
This trial tests whether Gamunex, an antibody replacement therapy, helps patients with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma who have low immunoglobulin (antibody) levels. The treatment may reduce infections and improve how well the body fights disease.
St. Petersburg, FloridaAges 18 years+ - NCT07620275RecruitingPhase 1
CD19/BCMA CAR-T Cell Therapy for Relapsed Multiple Myeloma
This trial tests KSVCBD, a cell therapy designed to target and attack myeloma cancer cells that express CD19 or BCMA proteins. It's for patients with multiple myeloma that has returned or stopped responding after previous treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07638683RecruitingPhase 2
Teclistamab and Daratumumab for New Multiple Myeloma With Amyloidosis
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
ShanghaiAges 18 years+ - NCT07642362Recruiting
Digital Support to Improve Quality of Life in Multiple Myeloma
This trial tests a digital app designed to help people with multiple myeloma (a blood cancer) manage their quality of life and symptoms. The study wants to see if using this app on a phone or computer can help patients feel better and stay connected to their care.
AthensAges Any age - NCT07663253Recruiting
Isatuximab with VRd for newly diagnosed multiple myeloma patients not eligible for transplant
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07410403Enrolling by invitation
AI study to predict genetic changes in myeloma cells
This trial uses artificial intelligence to look at individual myeloma cells under a microscope to predict genetic abnormalities (FISH results). It may help doctors understand your myeloma better without waiting for a separate FISH test.
Wuhan, HubeiAges Any age - NCT07210047Enrolling by invitationPhase 1/Phase 2
Study of HuL001 for multiple myeloma that has come back or not responded
This trial tests a new drug called HuL001 combined with lenalidomide and dexamethasone for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It aims to see if this combination can help when other options have failed.
TaipeiAges 18 years+ - NCT07763054Recruiting
Low-dose antifungal prevention for patients with low white blood cell counts
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
Hainan, HainanAges 18–75 - NCT05444348Recruiting
Communication and care-planning support for blood cancer patients
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
AalborgAges 18 years+ - NCT05837884Recruiting
Predicting who may develop myeloma in high-risk people
This study tries to predict which people at higher risk will develop myeloma (a blood cancer) and how quickly. It may help doctors spot problems earlier in people with family history and offer better follow-up.
BeershebaAges 30 years+ - NCT06262789Recruiting
Returning to work after blood cancer treatment
This study helps people who have finished treatment for a blood cancer (like leukemia or lymphoma) figure out the best way to return to work. It looks at what support might be needed during this transition.
AngersAges 18–55 - NCT07665307Recruiting
Delayed side effects after CAR-T for multiple myeloma
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
San Francisco, CaliforniaAges 18 years+ - NCT07751783Recruiting
Exercise program for cancer survivors
This trial helps people who have finished cancer treatment start a supervised exercise routine to improve their health. It tests whether a structured program with professional guidance is safe and helpful.
Kaohsiung, TaiwanAges 18–80 - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT06483100RecruitingPhase 2
Elranatamab after stem cell transplant for multiple myeloma
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
St Louis, MissouriAges 18 years+
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 574 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.